These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 10720289

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Whole brain volume changes in patients with progressive MS treated with cladribine.
    Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G.
    Neurology; 2000 Dec 12; 55(11):1714-8. PubMed ID: 11113227
    [Abstract] [Full Text] [Related]

  • 4. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.
    Giovannoni G, Cook S, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett A, Viglietta V, Greenberg S, CLARITY study group.
    Lancet Neurol; 2011 Apr 12; 10(4):329-37. PubMed ID: 21397565
    [Abstract] [Full Text] [Related]

  • 5. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial.
    Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, Vermersch P, Casset-Semanaz F, Scaramozza M, oral cladribine for early MS (ORACLE MS) Study Group.
    Lancet Neurol; 2014 Mar 12; 13(3):257-67. PubMed ID: 24502830
    [Abstract] [Full Text] [Related]

  • 6. The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis.
    Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, Nunn A, Cano MG, MacManus D, Miller D, Mallik S, Zajicek J.
    Health Technol Assess; 2015 Feb 12; 19(12):vii-viii, xxv-xxxi, 1-187. PubMed ID: 25676540
    [Abstract] [Full Text] [Related]

  • 7. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ.
    Clin Ther; 2006 Apr 12; 28(4):461-74. PubMed ID: 16750460
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
    Comi G, Cook SD, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Vermersch P, Hamlett AC, Viglietta V, Greenberg SJ.
    J Neurol; 2013 Apr 12; 260(4):1136-46. PubMed ID: 23263473
    [Abstract] [Full Text] [Related]

  • 10. The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation.
    Leist TP, Vermersch P.
    Curr Med Res Opin; 2007 Nov 12; 23(11):2667-76. PubMed ID: 17880754
    [Abstract] [Full Text] [Related]

  • 11. Cladribine in treatment of chronic progressive multiple sclerosis.
    Sipe JC, Romine JS, Koziol JA, McMillan R, Zyroff J, Beutler E.
    Lancet; 1994 Jul 02; 344(8914):9-13. PubMed ID: 7912347
    [Abstract] [Full Text] [Related]

  • 12. Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.
    Mao Z, Álvarez-González C, Allen-Philbey K, De Trane S, Yildiz O, Campion T, Adams A, Turner BP, Marta M, Gnanapavan S, Espasandin M, Mathews J, Giovannoni G, Baker D, Schmierer K.
    Mult Scler Relat Disord; 2019 Jan 02; 27():247-253. PubMed ID: 30419510
    [Abstract] [Full Text] [Related]

  • 13. Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients.
    Adams HP, Wagner S, Sobel DF, Slivka LS, Sipe JC, Romine JS, Beutler E, Koziol JA.
    Eur Neurol; 1999 Jul 02; 42(1):52-63. PubMed ID: 10394049
    [Abstract] [Full Text] [Related]

  • 14. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation.
    Karussis DM, Meiner Z, Lehmann D, Gomori JM, Schwarz A, Linde A, Abramsky O.
    Neurology; 1996 Aug 02; 47(2):341-6. PubMed ID: 8757002
    [Abstract] [Full Text] [Related]

  • 15. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
    Panitch H, Miller A, Paty D, Weinshenker B, North American Study Group on Interferon beta-1b in Secondary Progressive MS.
    Neurology; 2004 Nov 23; 63(10):1788-95. PubMed ID: 15557491
    [Abstract] [Full Text] [Related]

  • 16. Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
    Cree BAC, Bowen JD, Hartung HP, Vermersch P, Hughes B, Damian D, Hyvert Y, Dangond F, Galazka A, Grosso M, Jones DL, Leist TP.
    Mult Scler Relat Disord; 2021 Apr 23; 49():102695. PubMed ID: 33578191
    [Abstract] [Full Text] [Related]

  • 17. A comparison of two neurologic scoring instruments for multiple sclerosis.
    Koziol JA, Frutos A, Sipe JC, Romine JS, Beutler E.
    J Neurol; 1996 Mar 23; 243(3):209-13. PubMed ID: 8936349
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of Intravenous Cladribine in Patients with Rapidly Evolving or Early Secondary Progressive Multiple Sclerosis.
    Alshamrani F, Alnajashi H, Almuaigel MF.
    Cureus; 2020 Feb 14; 12(2):e6995. PubMed ID: 32206459
    [Abstract] [Full Text] [Related]

  • 19. Safety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis.
    Selby R, Brandwein J, O'Connor P.
    Can J Neurol Sci; 1998 Nov 14; 25(4):295-9. PubMed ID: 9827230
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.